Issues
Deals
Research
Ledger
About
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
Next issue
Issue 23 · Tue 17 Nov
All issues
Definium Therapeutics
Every issue covering Definium Therapeutics.
3 issues
2026-09-15
No. 14
Five countries, one regulator.
TRIALS
DEALS
REGULATORY
DEFINIUM
LILLY
ATAIBECKLEY
COMPASS
GH
2026-09-08
No. 13
Three authorised, one counted.
TRIALS
REGULATORY
SLAGELSE
CHIETI
AMSTERDAM-UMC
ARQ
DEFINIUM
2026-06-30
No. 4
LSD just posted the biggest depression number in psychedelic Phase 3 history.
TRIALS
RESEARCH
DEFINIUM
COMPASS